SCHEMBL2530707

SCHEMBL2530707

O=C(Nc1nc2ccc(Sc3cnc4ccc(-c5cnn(C6CCNCC6)c5)cn34)cc2s1)C1CC1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MET P08581 2/20 0.46
ABL1 P00519 8/20 0.44
DYRK1A Q13627 4/20 0.42
SNCA P37840 1/20 0.42
PIK3CD O00329 1/20 0.41
PIK3CA P42336 1/20 0.41
PIK3CB P42338 1/20 0.41
PI4KA P42356 1/20 0.41
PIK3CG P48736 1/20 0.41
PI4KB Q9UBF8 1/20 0.41
CASP3 P42574 1/20 0.41
SENP8 Q96LD8 1/20 0.41
SENP7 Q9BQF6 1/20 0.41
SENP6 Q9GZR1 1/20 0.41
GSK3B P49841 3/20 0.40
KIT P10721 1/20 0.40
PDGFRA P16234 1/20 0.40
PIM1 P11309 1/20 0.40
PIM2 Q9P1W9 1/20 0.40
MAP4K1 Q92918 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL2529747 0.99 MET (0.45) METABL1DYRK1ASNCAPIK3CD
SCHEMBL1827751 0.90 MET (0.46) METABL1DYRK1APIK3CDPIK3CA
SCHEMBL2539335 0.88 MET (0.54) METABL1PDE3BPDE3A
SCHEMBL2530990 0.88 LIPC (0.49) METABL1DYRK1AGSK3BPDE3B
Hydrochloric Acid SCHEMBL2543903 0.88 MET (0.54) METABL1PDE3BPDE3A
SCHEMBL2534423 0.87 MET (0.49) METABL1DYRK1ACASP3SENP8
SCHEMBL2530711 0.84 MET (0.61) METABL1PIK3CACASP3SENP8
SCHEMBL1839889 0.83 MET (0.51) METABL1CASP3SENP8SENP7
SCHEMBL2529642 0.82 MET (0.54) METABL1PIK3CACASP3SENP8
SCHEMBL2536920 0.81 ABL1 (0.52) METABL1KITPDGFRAMAP4K1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110257171-A1 NOVEL IMIDAZO[1,2-A]PYRIDINE DERIVATIVES, METHOD FOR THE PREPARATION THEREOF, USE THEREOF AS MEDICAMENTS, PHARMACEUTICAL COMPOSITIONS AND NOVEL USE IN PARTICULAR AS MET INHIBITORS SANOFI-AVENTIS (FR) 2011-10-20 US claimed
US-20110257171-A1 NOVEL IMIDAZO[1,2-A]PYRIDINE DERIVATIVES, METHOD FOR THE PREPARATION THEREOF, USE THEREOF AS MEDICAMENTS, PHARMACEUTICAL COMPOSITIONS AND NOVEL USE IN PARTICULAR AS MET INHIBITORS SANOFI-AVENTIS (FR) 2011-10-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110257171-A1 NOVEL IMIDAZO[1,2-A]PYRIDINE DERIVATIVES, METHOD FOR THE PREPARATION THEREOF, USE THEREOF AS MEDICAMENTS, PHARMACEUTICAL COMPOSITIONS AND NOVEL USE IN PARTICULAR AS MET INHIBITORS MET, ALK, RET MET 1/4885ABL1 43/4885DYRK1A 777/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.